Cardiosense Presents New Analysis of the SEISMIC-HF I Study Validating its AI Algorithm for Noninvasive PCWP Assessment at the American Heart Association’s 2025 Scientific Sessions
Cardiosense Presents New Clinical Analysis of SEISMIC-HF I Data on AI-Enabled Volume Assessment in Heart Failure at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 Scientific Symposium
Cardiosense Appoints Eric Meizlish as CEO to Advance AI-Enabled Cardiac Care
Cardiosense Appoints Medtech Executive John Martin, MD as EVP and Chief Medical Officer
Cardiosense Receives FDA 510(k) Clearance for the CardioTagTM Device, Paving the Way for Advanced Cardiac Function Monitoring
Cardiosense Announces Publication of SEISMIC-HF I Study Results in the Journal of the American College of Cardiology: Heart Failure
Cardiosense Launches Nationwide SEISMIC-HF II Study to Validate Its AI Algorithm for Non-Invasive Heart Failure Management
Cardiosense Noninvasively Measures Heart Failure’s Key Warning Signal
Results from Cardiosense’s SEISMIC-HF I Study of a Machine Learning Model to Non-Invasively Assess Cardiac Filling Pressure Presented as Late-Breaking Science at American Heart Association’s 2024 Scientific Sessions
Cardiosense Presents Interim Clinical Study Data for Machine Learning Algorithm to Aid in Heart Failure Management at the Transcatheter Cardiovascular Therapeutics (TCT) 2024 Scientific Symposium
